>
Switch to:

Allergy Therapeutics PE Ratio

: 232.00 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2021-10-17), Allergy Therapeutics's share price is $0.464. Allergy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00. Therefore, Allergy Therapeutics's PE Ratio for today is 232.00.

Warning Sign:

Allergy Therapeutics PLC stock PE Ratio (=121.84) is close to 5-year high of 121.84


The historical rank and industry rank for Allergy Therapeutics's PE Ratio or its related term are showing as below:

OTCPK:AGYTF' s PE Ratio Range Over the Past 10 Years
Min: 10.23   Med: 60.63   Max: 307.5
Current: 121.83

10.23
307.5

During the past 13 years, the highest PE Ratio of Allergy Therapeutics was 307.50. The lowest was 10.23. And the median was 60.63.


OTCPK:AGYTF's PE Ratio is ranked lower than
99.99% of the 64 Companies
in the Drug Manufacturers industry.

( Industry Median: 23.00 vs. OTCPK:AGYTF: 121.83 )

Allergy Therapeutics's Earnings per Share (Diluted) for the six months ended in Jun. 2021 was $-0.03. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00.

As of today (2021-10-17), Allergy Therapeutics's share price is $0.464. Allergy Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00. Therefore, Allergy Therapeutics's PE Ratio without NRI for today is 232.00.

During the past 13 years, Allergy Therapeutics's highest PE Ratio without NRI was 307.50. The lowest was 10.23. And the median was 60.63.

Allergy Therapeutics's EPS without NRI for the six months ended in Jun. 2021 was $-0.03. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00.

During the past 12 months, Allergy Therapeutics's average EPS without NRI Growth Rate was -63.60% per year.

During the past 13 years, Allergy Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 66.90% per year. The lowest was -100.00% per year. And the median was -18.15% per year.

Allergy Therapeutics's EPS (Basic) for the six months ended in Jun. 2021 was $-0.03. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 was $0.00.


Allergy Therapeutics PE Ratio Historical Data

The historical data trend for Allergy Therapeutics's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss 28.00 12.73 62.50

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.00 N/A 12.73 N/A 62.50

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics PE Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's PE Ratio distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's PE Ratio falls into.



Allergy Therapeutics PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Allergy Therapeutics's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=0.464/0.002
=232.00

Allergy Therapeutics's Share Price of today is $0.464.
For company reported semi-annually, Allergy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio or PE Ratio (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Allergy Therapeutics  (OTCPK:AGYTF) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Allergy Therapeutics PE Ratio Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)